Medical Attention for Nephropathy
The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) who received a nephropathy screening or monitoring test or had evidence of nephropathy during the measurement year.
Date Reviewed: November 4, 2018
Support
-
Group/Practice
Health Plan
Individual Clinician
Measure Info
MIPS 119
NQF 0062
CMS 119
NQF Endorsed
Measure Type
Process
Measure Steward
National Committee for Quality Assurance
Clinical Topic Area
Diabetes
Care Setting
Outpatient
Data Source
Claims
Electronic Health Records
Paper Medical Records
Registry
ACP supports MIPS measure ID# 119 (NQF ID# 0062): “Diabetes: Medical Attention for Nephropathy” because the opportunity for improvement is well documented, developers cite 2018 clinical recommendations of the American Diabetes Association on “Standards of Medical Care in Diabetes” to form the basis of the measure, the numerator and denominator are well defined, the denominator includes well specified and clinically appropriate exceptions to eligibility for the measure, and measurement is repeatable and precise.